30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

BIOAGE Labs Inc (BIOA)

Track

Over the last 90 days, BIOAGE Labs Inc. has seen significant insider selling, totaling $471,252.6. Notably, Chief Medical Officer Paul D. Rubin and CEO Kristen Fortney have executed multiple planned and proposed sales. The company's stock has experienced a 16.3% decline in the past 90 days, trading around 63% of its 52-week high.
Stock chart
Ticker: BIOA
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
RUBIN PAUL D
Chief Medical Officer
3 sales — total 471,253 USD
Planned sale 1 Apr 2026
Value US$827,306.06 | Price 159.09 | Shares 36,442
Planned sale 1 Apr 2026
Value US$4,342,759.33 | Price 465.94 | Shares 85,211
Proposed sale 1 Apr 2026
Value US$157,084.20 | Price 17.81 | Shares 8,820
Planned sale 2 Mar 2026
Value US$3,360,171.57 | Price 471.76 | Shares 80,894
Proposed sale 2 Mar 2026
Value US$1,809,499.88 | Price 459.20 | Shares 53,222
Planned sale 2 Feb 2026
Value US$139,368.75 | Price 18.75 | Shares 7,433
Planned sale 2 Feb 2026
Value US$139,368.75 | Price 18.75 | Shares 7,433
Proposed sale 2 Feb 2026
Value US$139,368.75 | Price 18.75 | Shares 7,433
Planned sale 13 Jan 2026
Value US$40,538.38 | Price 21.08 | Shares 1,923
Planned sale 13 Jan 2026
Value US$239,548.69 | Price 20.54 | Shares 11,663
Planned sale 13 Jan 2026
Value US$86,369.54 | Price 19.45 | Shares 4,440
Planned sale 13 Jan 2026
Value US$165,371.08 | Price 18.43 | Shares 8,974
Proposed sale 13 Jan 2026
Value US$531,828.03 | Price 19.70 | Shares 27,000
Planned sale 13 Jan 2026
Value US$4,223,036.34 | Price 18.12 | Shares 233,107
Proposed sale 13 Jan 2026
Value US$4,195,926.00 | Price 18.00 | Shares 233,107
Planned sale 2 Jan 2026
Value US$95,490.26 | Price 12.85 | Shares 7,433
Proposed sale 2 Jan 2026
Value US$99,676.53 | Price 13.41 | Shares 7,433
Planned sale 9 Dec 2025
Value US$216,000.00 | Price 12.00 | Shares 18,000
Proposed sale 9 Dec 2025
Value US$216,000.00 | Price 12.00 | Shares 18,000
Planned sale 4 Dec 2025
Value US$701,908.86 | Price 10.19 | Shares 68,897
Proposed sale 4 Dec 2025
Value US$701,911.64 | Price 10.19 | Shares 68,897
Buy 3 Oct 2024
Value US$503,589.40 | Price 19.90 | Shares 25,306
Buy 2 Oct 2024
Value US$1,323,804.08 | Price 19.73 | Shares 67,096
Buy 1 Oct 2024
Value US$2,501,625.89 | Price 19.73 | Shares 126,793
Buy 27 Sep 2024
Value US$47,376.00 | Price 18.00 | Shares 2,632
Buy 27 Sep 2024
Value US$8,100,000.00 | Price 18.00 | Shares 450,000
Buy 27 Sep 2024
Value US$476,946.00 | Price 18.00 | Shares 26,497
Buy 27 Sep 2024
Value US$392,652.00 | Price 18.00 | Shares 21,814
Buy 27 Sep 2024
Value US$330,354.00 | Price 18.00 | Shares 18,353
Buy 27 Sep 2024
Value US$200,034.00 | Price 18.00 | Shares 11,113
Buy 27 Sep 2024
Value US$10,599,984.00 | Price 18.00 | Shares 588,888
Buy 27 Sep 2024
Value US$7,200,000.00 | Price 18.00 | Shares 400,000
Buy 27 Sep 2024
Value US$16,200,000.00 | Price 18.00 | Shares 900,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-03 2026-04-01 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
36,442 -38.1%
159.09
US$827,306 		36,442 -38.1% 159.09 US$827,306
2026-04-03 2026-04-01 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
85,211 -12.4%
465.94
US$4,342,759 		85,211 -12.4% 465.94 US$4,342,759
2026-04-01 2026-04-01 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
80,144
448.21
US$4,315,873 		80,144 448.21 US$4,315,873
2026-03-03 2026-03-02 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
7,433 -100.0%
20.30
US$150,890 		7,433 -100.0% 20.30 US$150,890
2026-03-02 2026-03-02 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
7,433
20.03
US$148,883 		7,433 20.03 US$148,883
2026-02-03 2026-02-02 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
7,433 -100.0%
18.75
US$139,369 		7,433 -100.0% 18.75 US$139,369
2026-02-03 2026-02-02 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
7,433 -100.0%
18.75
US$139,369 		7,433 -100.0% 18.75 US$139,369
2026-02-02 2026-02-02 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
7,433
18.75
US$139,369 		7,433 18.75 US$139,369
2026-01-15 2026-01-13 PlS Planned sale
0.6
GOLDSTEIN DOV A MD

Chief Financial Officer

Officer
1,923 -7.9%
21.08
US$40,538 		1,923 -7.9% 21.08 US$40,538
2026-01-15 2026-01-13 PlS Planned sale
0.6
GOLDSTEIN DOV A MD

Chief Financial Officer

Officer
11,663 -32.4%
20.54
US$239,549 		11,663 -32.4% 20.54 US$239,549
2026-01-15 2026-01-13 PlS Planned sale
0.6
GOLDSTEIN DOV A MD

Chief Financial Officer

Officer
4,440 -11.0%
19.45
US$86,370 		4,440 -11.0% 19.45 US$86,370
2026-01-15 2026-01-13 PlS Planned sale
0.6
GOLDSTEIN DOV A MD

Chief Financial Officer

Officer
8,974 -18.2%
18.43
US$165,371 		8,974 -18.2% 18.43 US$165,371
2026-01-15 2026-01-13 PlS Planned sale
Fortney Kristen

Chief Executive Officer

Executive Director
233,107 -19.3%
18.12
US$4,223,036 		233,107 -19.3% 18.12 US$4,223,036
2026-01-13 2026-01-13 PrS Proposed sale
Fortney Kristen

10% Stockholder

Large shareholder
233,107
18.00
US$4,195,926 		233,107 18.00 US$4,195,926
2026-01-13 2026-01-13 PrS Proposed sale
0.6
GOLDSTEIN DOV A MD

Officer

Officer
27,000
19.70
US$531,828 		27,000 19.70 US$531,828
2026-01-06 2026-01-02 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
7,433 -100.0%
12.85
US$95,490 		7,433 -100.0% 12.85 US$95,490
2026-01-02 2026-01-02 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
7,433
13.41
US$99,677 		7,433 13.41 US$99,677
2025-12-11 2025-12-09 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
18,000 -100.0%
12.00
US$216,000 		18,000 -100.0% 12.00 US$216,000
2025-12-09 2025-12-09 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
18,000
12.00
US$216,000 		18,000 12.00 US$216,000
2025-12-05 2025-12-04 PlS Planned sale
RUBIN PAUL D

Chief Medical Officer

Officer
68,897 -100.0%
10.19
US$701,909 		68,897 -100.0% 10.19 US$701,909
2025-12-04 2025-12-04 PrS Proposed sale
RUBIN PAUL D

Officer

Officer
68,897
10.19
US$701,912 		68,897 10.19 US$701,912
2024-10-03 2024-10-03 B Purchase
1.7
Pande Vijay Satyanand
Non-Executive Director
25,306 +2.3%
19.90
US$503,589 		25,306 +2.3% 19.90 US$503,589
2024-10-03 2024-10-02 B Purchase
1.7
Pande Vijay Satyanand
Non-Executive Director
67,096 +6.5%
19.73
US$1,323,804 		67,096 +6.5% 19.73 US$1,323,804
2024-10-03 2024-10-01 B Purchase
1.7
Pande Vijay Satyanand
Non-Executive Director
126,793 +14.1%
19.73
US$2,501,626 		126,793 +14.1% 19.73 US$2,501,626
2025-03-10 2024-09-27 B Purchase
Barton Shane

Principal Accounting Officer

Officer
2,632 +inf%
18.00
US$47,376 		2,632 +inf% 18.00 US$47,376
2024-10-01 2024-09-27 B Purchase
3.8
Cormorant Asset Management, LP

Former 10% Owner
450,000 +38.2%
18.00
US$8,100,000 		450,000 +38.2% 18.00 US$8,100,000
2024-09-27 2024-09-27 B Purchase
2.9
HEALY JAMES
Non-Executive Director
26,497 +inf%
18.00
US$476,946 		26,497 +inf% 18.00 US$476,946
2024-09-27 2024-09-27 B Purchase
2.9
HEALY JAMES
Non-Executive Director
21,814 +inf%
18.00
US$392,652 		21,814 +inf% 18.00 US$392,652
2024-09-27 2024-09-27 B Purchase
2.9
HEALY JAMES
Non-Executive Director
18,353 +inf%
18.00
US$330,354 		18,353 +inf% 18.00 US$330,354
2024-09-27 2024-09-27 B Purchase
2.9
HEALY JAMES
Non-Executive Director
11,113 +inf%
18.00
US$200,034 		11,113 +inf% 18.00 US$200,034
2024-09-27 2024-09-27 B Purchase
2.9
HEALY JAMES
Non-Executive Director
588,888 +35.9%
18.00
US$10,599,984 		588,888 +35.9% 18.00 US$10,599,984
2024-09-27 2024-09-27 B Purchase
3.6
ENRIGHT PATRICK G
Non-Executive Director
400,000 +30.5%
18.00
US$7,200,000 		400,000 +30.5% 18.00 US$7,200,000
2024-09-27 2024-09-27 B Purchase
1.7
Pande Vijay Satyanand
Non-Executive Director
900,000 +inf%
18.00
US$16,200,000 		900,000 +inf% 18.00 US$16,200,000
Explore more

More insider trading research around BIOAGE Labs Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America